Cancer Treatment Gets a Boost with Radixact System in Mumbai
A Mumbai hospital has introduced the Radixact® Treatment Delivery System, a new radiation therapy technology aimed at improving accuracy in cancer treatment and reducing harm to healthy tissue.
The system combines real-time imaging with adaptive targeting, allowing doctors to adjust radiation delivery as the patient's body moves—such as during breathing. A built-in CT scanner helps ensure the tumor remains accurately targeted throughout the procedure.
According to the hospital, this upgrade is part of ongoing efforts to improve cancer care through more precise, individualized treatment. The system is capable of treating a variety of cancers and is designed to deliver higher doses of radiation with fewer side effects.
The hospital has also invested in genomic testing and precision oncology infrastructure. A 500-gene cancer panel is being used to support more tailored treatment plans based on a tumor's genetic profile.
precision and efficiency.
Dr Santosh Shetty, Executive Director and CEO of Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute said, 'At Kokilaben Hospital, we are constantly pushing the boundaries of medical innovation to ensure our patients receive the most advanced and effective treatment. The adoption of the globally acclaimed Radixact® system marks a major leap forward in our commitment to delivering world-class cancer care. As a centre that continues to be recognized for its leadership in oncology, we are proud to bring one of the most sophisticated radiation technologies to India. This upgrade reaffirms our dedication to adopting global standards that improve both clinical outcomes and quality of care .'
The adoption of the Radixact system comes amid a growing cancer burden in India. Health experts say timely access to accurate diagnosis and targeted treatment remains a challenge for many patients, and that such technologies could help improve survival rates and reduce complications.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Modella AI Announces Agreement to Accelerate AI-Driven Oncology Clinical Development
BOSTON--(BUSINESS WIRE)-- Modella AI, a leader in artificial intelligence for life sciences, today announced a multi-year agreement with AstraZeneca. Under the agreement, Modella AI will provide access to its state-of-the-art multi-modal AI foundation models to AstraZeneca. This agreement aims to harness Modella AI's advanced foundation models, capable of rich feature extraction from diverse data types, to accelerate clinical development across AstraZeneca's global oncology portfolio. 'Foundation models are transforming precision medicine. They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents,' said Jill Stefanelli, CEO of Modella AI. 'Our state-of-the-art multimodal foundation models provide powerful features from different data types for downstream tasks. When integrated with AstraZeneca's research engine, they will have the potential to accelerate data driven development and enable the development of new AI agents that can automate complex R&D workflows.' AstraZeneca will leverage Modella AI's platform to enhance its oncology R&D capabilities, with the goal of enhancing clinical development, biomarker discovery, and improving patient outcomes. Both companies will collaborate closely to integrate the models into AstraZeneca's research pipeline, enabling data-driven discovery at increased scale and speed. 'At AstraZeneca, AI is integrated across every aspect of clinical development,' said Jorge Reis-Filho, Chief AI and Data Scientist, Oncology R&D, AstraZeneca. 'Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials.' About Modella AI Modella AI ( is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. By combining expertise in artificial intelligence and pathology, Modella AI aims to deliver innovative solutions that empower clinicians, improve patient outcomes, and transform medical workflows. Disclaimer: This release may contain forward-looking statements based on current assumptions and forecasts made by Modella AI management. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Indianapolis Star
3 hours ago
- Indianapolis Star
Viemed Completes Acquisition of Lehan's Medical Equipment Anticipates Updating its Full Year 2025 Outlook for the Acquisition with Second Quarter 2025 Financial Results
LAFAYETTE, LA / ACCESS Newswire Viemed Healthcare, Inc. (the 'Company' or 'Viemed') (NASDAQ: VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has completed the previously disclosed acquisition of Illinois-based Lehan's Medical Equipment ('Lehan') for a base purchase price of $26 million, subject to customary adjustments, plus estimated contingent payments of $2.2 million. 'We are pleased to close the acquisition of Lehan and bring this talented and highly motivated team into the Viemed family,' said Viemed Chief Executive Officer Casey Hoyt. 'Lehan's 80-year track record and brand recognition in a large and fast-growing market along with its preferred contracts and fulfillment expertise make for a powerful combination with our national scale, unique care delivery model and existing payer relationships to serve a broader patient population.' In 2024, Lehan generated net revenues of approximately $25.7 million and Adjusted EBITDA of approximately $7.4 million. See 'Non-GAAP Financial Measures' for a discussion of Adjusted EBITDA. Viemed funded the acquisition through a combination of cash on hand and borrowings from its existing credit facilities. Viemed anticipates increasing its previously issued full-year 2025 guidance range to account for the expected contribution from this acquisition when it reports earnings results for the quarter ended June 30, 2025. Lehan's Medical Equipment is a healthcare provider offering home medical equipment and products for women's health, including breast pumps. The organization specializes in promoting wellness through a variety of healthcare services. Lehan also provides rental, sales, and resupply of CPAPs and other respiratory devices, as well as sales of other medical equipment. Lehan currently has three full-service locations in the Northern Illinois area and three sleep/CPAP set up locations in the West Chicagoland area, including one in Wisconsin. ABOUT VIEMED HEALTHCARE, INC. Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at For further information, please contact: Investor Relations ir@ Tripp Sullivan SCR Partners, LLC 615-942-7077 Trae Fitzgerald Chief Financial Officer Viemed Healthcare, Inc. 337-504-3802 Forward-Looking Statements Certain statements contained in this press release may constitute 'forward-looking statements' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or 'forward-looking information' as such term is defined in applicable Canadian securities legislation (collectively, 'forward-looking statements'). Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'expects', 'is expected', 'budget', 'potential', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', 'believes', 'projects', or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results 'will', 'should', 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved' or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's expectations about its acquisition of Lehan's Medical Equipment, such as contingent payments, anticipated benefits, and anticipated updates to the Company's 2025 financial guidance are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the 'SEC') available on the SEC's website at including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law. Non-GAAP Financial Measures This press release refers to 'Adjusted EBITDA' which is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. The Company's presentation of Adjusted EBITDA may not be comparable to similarly titled measures used by other companies. Adjusted EBITDA is defined as net income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and other adjustments, including adjustments relating to the proposed acquisition of Lehan. Company management believes Adjusted EBITDA provides helpful information to analyze Lehan's operating performance, including a view of Lehan's business that is not dependent on the impact of Lehan's capitalization structure and the exclusion of items that are not part of Lehan's recurring operations, including the impacts of the Company's proposed acquisition of Lehan. Accordingly, Company management believes that Adjusted EBITDA provides useful information in understanding and evaluating Lehan's historical operating performance in the same manner as it analyzes the Company's operating performance. SOURCE: Viemed Healthcare, Inc.
Business Insider
3 hours ago
- Business Insider
Citadel hires a chief medical officer as Ken Griffin pushes for 'peak performance'
Citadel employees are now not only being paid like elite athletes, but treated like them, too. The firm just hired former Morgan Stanley executive David Stark as its first-ever " chief medical officer," Business Insider has learned. The new role, which was announced Monday in an internal memo obtained by BI, is meant to "support peak performance" in employees at both the hedge fund and its sister market-making firm. The note said Stark, a neurologist who was previously in a similar role at Morgan Stanley, will start in September. "In this newly created role, David will be responsible for driving innovation in employee benefits and wellness to further enhance the employee experience and support peak performance of our colleagues," said Sjoerd Gehring, Citadel's chief people officer, who joined from Apple in November, said in the memo. This is the first in-house medical role for billionaire Ken Griffin's companies, according to a person with direct knowledge of the hire. Some offices have on-site medical clinics operated by third-party healthcare providers. Stark won't provide medical care, but will rework healthcare benefits, including concierge healthcare services, this person said. He'll also personalize health plans for the firm's employees. It's not only a new role for Citadel, but also the $5.7 trillion industry. Other hedge funds have had performance coaches, nutritionists, and even personal trainers on staff — Citadel has employed a global head of culinary for years, for example — but this is the first chief medical officer in the space, according to the person close to the Miami-based fund. It's another example of how the $66 billion hedge fund is more akin to an investment bank than its smaller asset management peers. Banks have long had these types of roles, in part to keep employees close to their desks so they can put in long hours with little interruption. Griffin has expressed admiration for the grueling work ethic required by many Wall Street institutions, specifically Goldman Sachs. Griffin, who has poached several Goldman executives to join his hedge fund and market-making firm, including Citadel Securities president Jim Esposito, said in 2020 at a talk with Goldman CFO John Waldron that leaders can't expect 9-to-5 schedules and "a great weekend." It's also not the first time the firm has offered employees extravagant work benefits. During the pandemic, Griffin rented out a hotel in Palm Beach as a makeshift trading floor so employees could work in a " bubble." He once treated Citadel and Citadel Securities employees and their families to a weekend at Disney World, which included a concert headlined by Coldplay. Even their summer internship this year started with a trip to the Four Seasons. According to the memo, Stark's background includes training as a pediatric neurologist at Harvard Medical School. Before his time at Morgan Stanley, he was a medical director at Mount Sinai Health System. Citadel views this as another way to help it stand out in the industry's talent war. "We believe this is a significant step forward, and one that will further differentiate Citadel as a place where exceptional people can achieve their highest potential," the memo said.
